Acetohexamide

Summary

Acetohexamide (CHEMBL1589) is an approved small-molecule hypoglycemic agent (ATC A10BB31); indicated across 2 conditions including diabetes mellitus and cataract.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A10BB31
• Indications: 2 conditions
• Chemistry: 324.4 Da · C15H20N2O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1589
Name	Acetohexamide
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	1989
ChEBI	CHEBI:28052
ATC	A10BB31
Molecular formula	C15H20N2O4S
Molecular weight	324.4
InChIKey	VGZSUPCWNCWDAN-UHFFFAOYSA-N

SMILES: CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC2CCCCC2

IUPAC name: 1-(4-acetylphenyl)sulfonyl-3-cyclohexylurea

ChEBI definition: An N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is replaced by a p-acetylphenylsulfonyl group, while a hydrogen attached to the other nitrogen is replaced by a cyclohexyl group.

Pharmacological roles (ChEBI): hypoglycemic agent, insulin secretagogue.

Also known as: Acetohexamida, Acetohexamide, Dimelor, Dymelor, NSC-759128, SID11110689, SID11112460, SID17390067, SID50105548, SID56463352, SID90341130, ACETOHEXAMIDE

Patent coverage: 4,438 distinct patent families (18,343 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 9 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Prelamin-A/C, RecQ-like DNA helicase BLM, 4’-phosphopantetheinyl transferase ffp, Thyroid hormone receptor beta, Thyrotropin receptor, Beta-lactamase, Muscarinic acetylcholine receptor M1, Aldehyde dehydrogenase 1A1.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 12 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
THRB	8.6	Potency	2.5	nM	CHEMBL_ACT_4017913
BLM	8.55	Potency	2.8	nM	CHEMBL_ACT_4746007
BLM	8.55	Potency	2.8	nM	CHEMBL_ACT_4925952
TSHR	8.2	Potency	6.3	nM	CHEMBL_ACT_3937527
TSHR	8.2	Potency	6.3	nM	CHEMBL_ACT_4707328

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
diabetes mellitus	4	MONDO:0005015	EFO:0000400
cataract	3	MONDO:0005129	MONDO:0005129

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).